COVID-19 and risk of long-term mortality in COPD: a nationwide population-based cohort study

被引:1
作者
Lee, Hyun [1 ]
Kim, Sang Hyuk [2 ,3 ]
Jeong, Cho Yun [4 ]
Chung, Jee-Eun [5 ]
Kim, Youlim [6 ]
Min, Kyung Hoon [2 ]
Yoo, Kwang Ha [6 ]
Kim, Jong Seung [4 ,7 ,8 ]
Moon, Ji-Yong [6 ]
机构
[1] Hanyang Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Korea Univ, Guro Hosp, Dept Internal Med, Div Pulm Allergy & Crit Care Med ,Coll Med, Seoul, South Korea
[3] Dongguk Univ, Gyeongju Hosp, Div Pulm Allergy & Crit Care Med, Dept Internal Med,Coll Med, Gyeongju, South Korea
[4] Jeonbuk Natl Univ, Med Sch, Dept Med Informat, Jeonju, South Korea
[5] Hanyang Univ, Coll Pharm, Seoul, South Korea
[6] Konkuk Univ, Sch Med, Med Ctr, Dept Internal Med, Seoul, South Korea
[7] Jeonbuk Natl Univ, Biomed Res Inst, Res Inst Clin Med, Jeonbuk Natl Univ Hosp, Jeonju, South Korea
[8] Jeonbuk Natl Univ, Med Sch, Dept Otorhinolaryngol Head & Neck Surg, Jeonju, South Korea
关键词
COVID-19; Pulmonary Disease; Chronic Obstructive; Respiratory Infection; Viral infection; OBSTRUCTIVE PULMONARY-DISEASE; EXACERBATIONS; HISTORY; ASTHMA;
D O I
10.1136/bmjresp-2024-002694
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Chronic obstructive pulmonary disease (COPD) is a risk factor for severe COVID-19. However, mortality after COVID-19 recovery in this population remains unclear.Methods We retrospectively enrolled individuals with COPD from the Korean National Health Insurance database. We compared the mortality rate in individuals with COPD who recovered from COVID-19 between 8 October 2020 and 31 December 2021 (COVID-19 cohort, n=2499) with that in 1:1 propensity score-matched controls (n=2499). The study population was followed until either death or 30 September 2022, whichever came first.Results The COVID-19 cohort had a 4.8% mortality rate vs 2.7% in matched controls during a median follow-up of 319 days (IQR, 293-422 days), including 14 days of recovery time. The COVID-19 cohort had a higher risk of death than matched controls (adjusted HR (aHR)=1.81, 95% CI=1.35 to 2.45). The risk of mortality was notably higher in individuals with severe COVID-19 (aHR=5.05, 95% CI=3.65 to 6.97), especially during the first 180 days of recovery (highest during the first 30 days (aHR=20.25, 95% CI=7.79 to 52.64)). Non-severe COVID-19 does not increase the risk of mortality compared with controls (aHR=0.85, 95% CI=0.57 to 1.28).Conclusion Individuals with COPD recovering from COVID-19 showed an increased risk of long-term mortality, particularly within the first 180 days post-recovery, especially those who experienced severe COVID-19.
引用
收藏
页数:9
相关论文
共 57 条
[1]   Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis [J].
Alqahtani, Jaber S. ;
Oyelade, Tope ;
Aldhahir, Abdulelah M. ;
Alghamdi, Saeed M. ;
Almehmadi, Mater ;
Alqahtani, Abdullah S. ;
Quaderi, Shumonta ;
Mandal, Swapna ;
Hurst, John R. .
PLOS ONE, 2020, 15 (05)
[2]  
[Anonymous], 2023, Global strategy for prevention, diagnosis and management of COPD: 2023 report
[3]   The Complex Association between COPD and COVID-19 [J].
Awatade, Nikhil T. ;
Wark, Peter A. B. ;
Chan, Andrew S. L. ;
Al Mamun, S. M. Abdullah ;
Esa, Nurul Yaqeen Mohd ;
Matsunaga, Kazuto ;
Rhee, Chin Kook M. ;
Hansbro, Philip M. ;
Sohal, Sukhwinder Singh .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (11)
[4]   Omicron: increased transmissibility and decreased pathogenicity [J].
Balint, Gabor ;
Voros-Horvath, Barbara ;
Szechenyi, Aleksandar .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
[5]   Severe Covid-19 [J].
Berlin, David A. ;
Gulick, Roy M. ;
Martinez, Fernando J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2451-2460
[6]   Hospitalized Patients With Severe Coronavirus Disease 2019 During the Omicron Wave in Israel: Benefits of a Fourth Vaccine Dose [J].
Brosh-Nissimov, Tal ;
Hussein, Khetam ;
Wiener-Well, Yonit ;
Orenbuch-Harroch, Efrat ;
Elbaz, Meital ;
Lipman-Arens, Shelly ;
Maor, Yasmin ;
Yagel, Yael ;
Chazan, Bibiana ;
Hershman-Sarafov, Mirit ;
Rahav, Galia ;
Zimhony, Oren ;
Zaidman Shimshovitz, Adi ;
Chowers, Michal .
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) :E234-E239
[7]   Impact of Rheumatoid Arthritis and Seropositivity on the Risk of Non-Cystic Fibrosis Bronchiectasis [J].
Choi, Hayoung ;
Han, Kyungdo ;
Jung, Jin Hyung ;
Park, Junhee ;
Kim, Bo-Guen ;
Yang, Bumhee ;
Eun, Yeonghee ;
Kim, Hyungjin ;
Shin, Dong Wook ;
Lee, Hyun .
CHEST, 2024, 165 (06) :1330-1340
[8]   Association between exercise and risk of cardiovascular diseases in patients with non-cystic fibrosis bronchiectasis [J].
Choi, Hayoung ;
Kim, Sang Hyuk ;
Han, Kyungdo ;
Park, Tai Sun ;
Park, Dong Won ;
Moon, Ji-Yong ;
Kim, Sang-Heon ;
Kim, Tae-Hyung ;
Sohn, Jang Won ;
Yoon, Ho Joo ;
Lee, Hyun .
RESPIRATORY RESEARCH, 2022, 23 (01)
[9]   Long-Term Mortality of Tuberculosis Survivors in Korea: A Population-based Longitudinal Study [J].
Choi, Hayoung ;
Han, Kyungdo ;
Jung, Jin-Hyung ;
Park, Sang Hyun ;
Kim, Sang Hyuk ;
Kang, Hyung Koo ;
Sohn, Jang Won ;
Shin, Dong Wook ;
Lee, Hyun .
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) :E973-E981
[10]   Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities [J].
Choi, Hayoung ;
Yang, Bumhee ;
Kim, Yun Jin ;
Sin, Sooim ;
Jo, Yong Suk ;
Kim, Youlim ;
Park, Hye Yun ;
Ra, Seung Won ;
Oh, Yeon-Mok ;
Chung, Sung Jun ;
Yeo, Yoomi ;
Park, Dong Won ;
Park, Tai Sun ;
Moon, Ji-Yong ;
Kim, Sang-Heon ;
Kim, Tae-Hyung ;
Yoon, Ho Joo ;
Sohn, Jang Won ;
Lee, Hyun .
SCIENTIFIC REPORTS, 2021, 11 (01)